16. Crow-Fukase syndrome
12 clinical trials,   18 drugs   (DrugBank: 8 drugs),   5 drug target genes,   79 drug target pathways

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04396496
(ClinicalTrials.gov)
September 22, 202015/5/2020Treatment of POEMS Syndrome With DaratumumabA Phase II Trial for the Treatment of POEMS Syndrome With DaratumumabPOEMS SyndromeDrug: Daratumumab InjectionUniversity of ArkansasJanssen Scientific Affairs, LLCRecruiting18 YearsN/AAll10Phase 2United States
2NCT02921893
(ClinicalTrials.gov)
October 31, 201626/9/2016Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Recruiting18 YearsN/AAll34Phase 2United States
3JPRN-jRCTs031180421
15/08/201625/03/2019LDCY-POEMS studyPhase II study of efficiency of peripheral blood stem cell harvest using low-dose cyclophosphamide plus G-CSF for POEMS syndrome POEMS syndrome
POEMS syndrome
Treatment by cyclophosphamide, mesna, graniserton, and lenograstim. Autologous peripheral blood stem cell harvest (auto-PBSCH)Sakaida EmikoNULLRecruiting>= 20age old<= 70age oldBoth14Phase 2Japan
4JPRN-UMIN000018660
2015/08/1717/08/2015Japanese POEMS syndrome with thalidmaide trial for compassionate useJapanese POEMS syndrome with thalidmaide trial for compassionate use - Japanese POEMS syndrome with thalidmaide trial for compassionate use (JPOST15) Crow-Fukase(POEMS) syndromeFPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4)

Duration:until the approval of thalidomide for POEMT syndrome
Chiba University Graduate School of MedicineNULLRecruiting20years-oldNot applicableMale and Female20Not selectedJapan
5JPRN-UMIN000018385
2015/07/0122/07/2015Phase II study of efficiency of peripheral blood stem cell harvest in POEMS syndrome patients with low-dose cyclophosphamide plus G-CSF POEMS syndromeThis study is composed of the following two steps of therapy.
1)PBSC mobilization using low dose cyclophosphamide and G-CSF
2)autologous peripheral stem cell transplantation after high dose chemotherapy
Chiba University HospitalDepartment of HematologyNULLPending20years-old70years-oldMale and Female14Phase 2Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02193698
(ClinicalTrials.gov)
July 201416/7/2014Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome TrialSingle Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) SyndromePOEMS SyndromeDrug: Lenalidomide+DexamethasoneChiba UniversityNULLCompleted20 YearsN/ABoth5Phase 2Japan
7NCT01816620
(ClinicalTrials.gov)
March 201414/3/2013Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeAn Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeDrug: Lenalidomide, DexamethasonePeking Union Medical College HospitalCelgene CorporationCompleted18 YearsN/AAll41Phase 2China
8NCT01639898
(ClinicalTrials.gov)
July 20125/7/2012POEMS Syndrome Treatment With LenalidomidePhase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.POEMS SyndromeDrug: Lenalidomide and dexamethasoneUniversity Hospital, LimogesMinistry of Health, France;Celgene CorporationCompleted18 YearsN/AAll51Phase 2France
9JPRN-JMA-IIA00084
22/03/201219/03/2012Japanese POEMS Syndrome with Thalidomide TrialJapanese POEMS Syndrome with Thalidomide Trial Crow-Fukase (POEMS) syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityCompleted>=20 YEARSNo LimitBOTH24Phase 3Japan
10JPRN-JMA-IIA00046
13/09/201006/09/2010Japanese POEMS Syndrome with Thalidomide TrialThalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety Crow-Fukase (POEMS)syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityCompleted>=20 YEARSNo LimitBOTH24Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2008-003202-33-IT
(EUCTR)
15/09/200917/11/2009Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 POEMS SYNDROME
MedDRA version: 9.1;Level: SOC;Classification code 10029205
Trade Name: REVLIMID*21CPS 25MG
INN or Proposed INN: Lenalidomide
ISTITUTO CLINICO HUMANITASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
12NCT00971685
(ClinicalTrials.gov)
July 20093/9/2009The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasNULLRecruiting18 YearsN/ABoth16Phase 2Italy